New Clinical Guidelines Issued for Adult Migraine Prevention

The American Academy of Neurology and American Headache Society released updated evidence-based guidelines on August 31, 2026, to assist clinicians in selecting effective migraine prevention medications.

The new recommendations apply to both episodic and chronic migraine patients, specifically targeting those experiencing four or more migraine or moderate-to-severe headache days per month.

Clinicians are advised to evaluate treatment effectiveness based on specific timeframes and consider patient quality of life, side effects, and costs when prescribing oral or injectable preventive therapies.